Innovation Pharmaceuticals Inc (IPIX)

[wsbc]

An interesting comment from a virologist-friend a few months back related to anti-virals needing to be 100% effective as anti-virals, or they're 100% ineffective.

Requiring an extended dosing period in the COVID trial makes me feel like it's not close to 100% effective as an anti-viral. Concerning? Hopefully the other MOA's help in other ways somehow?

I haven't read through the materials yet, but more POC stuff from Leo is par for the course for this company. Paying himself almost $1M this year alone for what? More tests? 15yrs of this company 'running more tests'. This is what shareholders are getting for their investment? Dilution and testing? Testing that doesn't even apply to the real world nonetheless!

In vitro data presented at ASV 2021 for Alphavirus and Bunyavirus used brilacidin at a concentration of 20µm and included pretreatment of the virus with brilacidin. The concentration of 20µm converts to a dose >1.5 mg/kg (almost 2X the highest single dose used in the ABSSSI P2 trial) while the pretreatment improves the potency of brilacidin. Both this dose and pretreatment of brilacidin are not possible when using brilacidin as a therapeutic in the real world. This is PoC stuff, and I know that investors were not the intended audience, but I was hoping for something to come out of it that would apply to the real world and move the share price.

2 slides seem to be missing from the deck. The slides are numbered 1-21 but there are 19 slides in the PDF. Slide 6 or 7 and 13 are not included.